Compare DexCom, Inc. (DXCM) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ProShares Ultra Gold ETF — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while ProShares Ultra Gold ETF trades at $46.48 (market cap $716.59M). The key difference: DexCom, Inc. is far larger — about 44.5× ProShares Ultra Gold ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and ProShares Ultra Gold ETF for 23 Days on average.
| DXCM | UGL | |
|---|---|---|
Market Cap | $31.86B | $716.59M |
Volume | 3,607,070 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.34 | $85.62 |
52-Week Low | $54.84 | $42.79 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
UGL trades at $46.47, up 4.59% in the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing to selling pressure. Key support lies at $44, while resistance is near $46. The stock lacks disclosed financial ratios, limiting fundamental visibility. Recent news highlights gold price volatility driven by Treasury yields and Federal Reserve policy expectations, influencing sentiment around gold-related equities.
The outlook remains cautious due to weak technical momentum and macroeconomic headwinds from rising rates. Investment opportunity hinges on gold price stabilization, but risks include persistent bearish indicators and sensitivity to interest rate changes. Investors should await clearer fundamental data and technical confirmation of a trend reversal before considering entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
